What the FDA labels say about taking them together
Adalimumab and theophylline
Adalimumab's FDA label of October 21, 2025 names theophylline in its drug interactions section; the theophylline label PlainMeds reads does not name adalimumab. The adalimumab label: “Upon initiation or discontinuation of HUMIRA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration is recommended and the …”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the theophylline FDA label on DailyMed (effective March 10, 2026, Strides Pharma Science Limited).
What does the adalimumab label say about theophylline?
Adalimumab label, drug interactionsUpon initiation or discontinuation of Adalimumab-adaz in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
Source: FDA drug label (Humira, BLA125057), AbbVie Inc., effective December 23, 2025 (SPL set 608d4f0d-b19f-46d3-749a-7159aa5f933d), via openFDA
Source: FDA drug label (Adalimumab-Aacf, BLA761255), Fresenius Kabi USA, LLC, effective January 8, 2026 (SPL set 2488b0bc-7b8f-4cc8-91ea-48e7ea5e8915), via openFDA
Source: FDA drug label (Yusimry, BLA761216), Coherus BioSciences Inc, effective May 16, 2025 (SPL set cd0e7af2-7704-49ce-bde9-f645294b6788), via openFDA
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the theophylline label say about adalimumab?
Theophylline's label (effective March 10, 2026) does not name adalimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Theophylline), Strides Pharma Science Limited, effective March 10, 2026 (SPL set b7a90ccf-9c32-40cc-9008-7e55b3da4dfd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Theophylline | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Asthma |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | $0.330 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once